Cargando…

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs

The objective of this work was to identify predictive factors of fibrosis regression after direct antiviral agents (DAAs) in HCV-monoinfected and HIV/HCV-coinfected patients. This was a prospective study of HCV-monoinfected (n = 20), HIV/HCV-co-infected (n = 66) patients and healthy controls (n = 15...

Descripción completa

Detalles Bibliográficos
Autores principales: Márquez-Coello, Mercedes, Arizcorreta, Ana, Rodríguez-Pardo, María, Illanes-Álvarez, Francisco, Márquez, Denisse, Cuesta-Sancho, Sara, Girón-González, José-Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110591/
https://www.ncbi.nlm.nih.gov/pubmed/33972651
http://dx.doi.org/10.1038/s41598-021-89370-6
_version_ 1783690331524431872
author Márquez-Coello, Mercedes
Arizcorreta, Ana
Rodríguez-Pardo, María
Illanes-Álvarez, Francisco
Márquez, Denisse
Cuesta-Sancho, Sara
Girón-González, José-Antonio
author_facet Márquez-Coello, Mercedes
Arizcorreta, Ana
Rodríguez-Pardo, María
Illanes-Álvarez, Francisco
Márquez, Denisse
Cuesta-Sancho, Sara
Girón-González, José-Antonio
author_sort Márquez-Coello, Mercedes
collection PubMed
description The objective of this work was to identify predictive factors of fibrosis regression after direct antiviral agents (DAAs) in HCV-monoinfected and HIV/HCV-coinfected patients. This was a prospective study of HCV-monoinfected (n = 20), HIV/HCV-co-infected (n = 66) patients and healthy controls (n = 15). Patients had started DAAs and achieved sustained virological response. Liver stiffness (LS) and serum concentrations of profibrotic transforming growth factor (TGF)-β1 and CXC chemokine ligand 4 (CXCL4) and antifibrotic HGF hepatocyte growth factor (HGF) were analyzed at baseline (M0) and 12 months after starting DAAs (M12). A M12 LS achievement of ≤ 9.5 kPa was considered the cutoff point to discharge from a liver clinic. The LS decrease from M0 to M12 was 34%. No significant differences were observed in LS decline between HCV- and HIV/HCV-infected individuals. Changes of serum CXCL4, TGF-β1 and HGF levels did not correlate with LS improvement. 16 out from 56 patients (28%) with a baseline LS > 9.5 achieved a M12 LS ≤ 9.5. HCV-monoinfected and HIV/HCV coinfected patients experienced a significant reduction of LS after sustained virological response. This improvement did not correlate with changes in serum profibrotic or antifibrotic markers. A 29% of those with a baseline LS > 9.5 achieved a LS under this cutoff point.
format Online
Article
Text
id pubmed-8110591
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81105912021-05-12 Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs Márquez-Coello, Mercedes Arizcorreta, Ana Rodríguez-Pardo, María Illanes-Álvarez, Francisco Márquez, Denisse Cuesta-Sancho, Sara Girón-González, José-Antonio Sci Rep Article The objective of this work was to identify predictive factors of fibrosis regression after direct antiviral agents (DAAs) in HCV-monoinfected and HIV/HCV-coinfected patients. This was a prospective study of HCV-monoinfected (n = 20), HIV/HCV-co-infected (n = 66) patients and healthy controls (n = 15). Patients had started DAAs and achieved sustained virological response. Liver stiffness (LS) and serum concentrations of profibrotic transforming growth factor (TGF)-β1 and CXC chemokine ligand 4 (CXCL4) and antifibrotic HGF hepatocyte growth factor (HGF) were analyzed at baseline (M0) and 12 months after starting DAAs (M12). A M12 LS achievement of ≤ 9.5 kPa was considered the cutoff point to discharge from a liver clinic. The LS decrease from M0 to M12 was 34%. No significant differences were observed in LS decline between HCV- and HIV/HCV-infected individuals. Changes of serum CXCL4, TGF-β1 and HGF levels did not correlate with LS improvement. 16 out from 56 patients (28%) with a baseline LS > 9.5 achieved a M12 LS ≤ 9.5. HCV-monoinfected and HIV/HCV coinfected patients experienced a significant reduction of LS after sustained virological response. This improvement did not correlate with changes in serum profibrotic or antifibrotic markers. A 29% of those with a baseline LS > 9.5 achieved a LS under this cutoff point. Nature Publishing Group UK 2021-05-10 /pmc/articles/PMC8110591/ /pubmed/33972651 http://dx.doi.org/10.1038/s41598-021-89370-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Márquez-Coello, Mercedes
Arizcorreta, Ana
Rodríguez-Pardo, María
Illanes-Álvarez, Francisco
Márquez, Denisse
Cuesta-Sancho, Sara
Girón-González, José-Antonio
Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
title Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
title_full Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
title_fullStr Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
title_full_unstemmed Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
title_short Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
title_sort modifications of liver stiffness and cxcl4, tgf-β1 and hgf are similar in hcv- and hiv/hcv-infected patients after daas
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110591/
https://www.ncbi.nlm.nih.gov/pubmed/33972651
http://dx.doi.org/10.1038/s41598-021-89370-6
work_keys_str_mv AT marquezcoellomercedes modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas
AT arizcorretaana modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas
AT rodriguezpardomaria modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas
AT illanesalvarezfrancisco modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas
AT marquezdenisse modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas
AT cuestasanchosara modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas
AT girongonzalezjoseantonio modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas